
Brain Cancers: FDA Approves Pembrolizumab Combo
Astrocytoma and glioblastoma are fast-growing brain cancers that often return after surgery. Survival for astrocytoma patients is generally four to five months. Medications that activate


Astrocytoma and glioblastoma are fast-growing brain cancers that often return after surgery. Survival for astrocytoma patients is generally four to five months. Medications that activate

Vanda Pharmaceuticals has achieved a significant regulatory milestone with the FDA’s approval of milsaperidone (Bysanti), a newly designated atypical antipsychotic medication poised to help adults

As reported by BioPharmaDive, he Food and Drug Administration (FDA) has intensified its oversight of companies marketing compounded GLP‑1 therapies, while Intellia Therapeutics, United Therapeutics,

For people living with Lynch syndrome, the threat of cancer is a constant shadow. This inherited condition affects about one in 300 people, making them

As reported on MedicalXpress, a new study published in Molecular Psychiatry suggests that a specific circular RNA found in blood, known as CDR1as, may help

As reported on BioPharmaDive, Aardvark Therapeutics has halted dosing and enrollment in its late‑stage HERO trial for ARD‑101, a first‑in‑class treatment candidate for Prader–Willi syndrome

Editor’s Note: Patient Worthy is pleased to bring you this article, originally shared with us by our friend Julie Lanford, The Cancer Dietitian. To see

The landscape of advanced breast cancer treatment is shifting. Genentech’s filing acceptance of giredestrant, an experimental oral medication, represents a pivotal moment for thousands of

As reported in Business Wire, Vico Therapeutics has initiated patient dosing in an expanded cohort of its Phase 1/2a clinical study evaluating VO659, an antisense

Editor’s Note: This article was shared with us by our friends at Heal Canada. To see the article in its original format, please click here.

AbbVie has announced a landmark regulatory milestone with the US FDA’s approval of a supplemental new drug application (sNDA) for the combination of Venclexta (venetoclax)

As published in Sleep Review Magazine, Axsome Therapeutics has officially begun dosing patients in its Phase 3 CLARITY trial, a study designed to evaluate solriamfetol

Fibrosis, the accumulation of scar tissue in organs, disrupts normal organ function and leads to progressive impairment. Currently, there is no cure, and existing treatments

The relationship between people with type 1 diabetes and their medication has always been complicated. For decades, managing the condition has required constant vigilance including

As reported on PharmaBiz, Harness Therapeutics has selected HRN001 as its lead therapeutic candidate for Huntington’s disease (HD), marking a major milestone for the company

Click here to see Part 1 of of this 3 part pain series. If you suffer with chronic pain, you not only live with the unrelenting

Patients using Zepbound for weight management now have a simpler option for administering their medication. As reported by PharmaLive.com, Eli Lilly received FDA clearance for

On this episode of Wait, How Do You Spell That?, host Bree Clare sits down with Dr. Charles Link, a pioneering oncologist whose career has
Spinal muscular atrophy (SMA) is a condition that many people may not hear about often, but for those living with it, it’s part of daily life. Raising awareness helps create understanding — not just about the condition itself, but about the strength, resilience, and challenges that come with it.
Learning about SMA helps us build a more informed and compassionate community where people affected by rare diseases feel seen, supported, and understood. Every conversation, every shared fact, and every moment of awareness helps bring more visibility to a condition that deserves it.
#SpinalMuscularAtrophy #SMA #RareDiseaseOfTheWeek #RareDisease #RareDiseaseAwareness #PatientWorthy
... See MoreSee Less

New research may offer hope for people living with #pku.
While still in development, this approach reflects growing momentum toward potentially durable, one-time genetic treatments for rare diseases.
patientworthy.com/2026/03/10/new-gene-editing-program-aims-to-address-root-cause-of-pku/
... See MoreSee Less

What is tardive dyskinesia? Keep reading to learn what this movement disorder is and what you need to know. Share your TD journey with us here: bit.ly/4dV7gru
#tardivedyskinesia #TDawareness #mentalhealthmatters #PatientWorthy
... See MoreSee Less

© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
What best describes you when it comes to rare disease? (check all that apply)
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.